BOSTON -- Pfizer's Diflucan (fluconazole) currently
dominates the antifungals market, thanks to a good safety profile, relatively
few drug-drug interactions, interchangeable oral and intravenous formulations,
and a highly successful marketing campaign. As generic competition erodes
fluconazole sales, beginning in 2004, Pfizer will try to maintain market
position with its next-generation drug, while Schering-Plough and Bristol-
Myers Squibb strive to gain market share with their novel therapeutics. Fungal
Opportunistic Infections in HIV, a new report from the Decision Resources,
Inc. Pharmacor service, provides an analysis for companies competing or
looking to compete in the market.
"Pfizer will attempt to shift usage to voriconazole," says Julia Bradsher,
Decision Resources' therapeutic area director for infectious disease. "This
market will be increasingly competitive as Schering-Plough's posaconazole and
Bristol-Myers Squibb's ravuconazole vie for marketshare, as well as pressure
from health care authorities and managed care insurers who favor the generic
version of fluconazole," Bradsher adds. Posaconazole's once-daily dosing and
favorable side-effect profile could create a valuable niche for Schering-
Plough in antifungal prophylaxis. Ravuconazole will enter a highly saturated
and competitive environment, but its long half-life may be an advantage in
future marketing campaigns if it translates into a shorter course of therapy.
Fungal Opportunistic Infections in HIV provides the following:
-- An overview of the etiology and pathophysiology of key HIV
opportunistic fungal infections.
-- Patient populations of oropharyngeal candidiasis, esophageal
candidiasis, and cryptococcosis in the seven major pharmaceutical
markets (the United States, France, Germany, Italy, Spain, the United
Kingdom, and Japan).
-- A survey of diagnosis and treatment practices in each of these markets.
-- An analysis of unmet needs in the treatment of fungal opportunistic
infections in HIV.
-- An evaluation of current and emerging drugs.
To generate this report, Decision Resources interviewed thought-leading
clinicians and researchers in each market and used a variety of drug audit
data (e.g., IMS Sales, Scott-Levin), analyst reports, publications, and
To order your copy of Fungal Opportunistic Infections in HIV call Frank
Sama at 781-296-2553 or email email@example.com.
Fungal Opportunistic Infections in HIV is part of the Infectious Disease
portfolio, one of six Pharmacor services that evaluate the commercial
potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research
publications, advisory services, and consulting designed to help clients shape
strategy, allocate resources, and master their chosen markets. Founded as a
subsidiary of Arthur D. Little, Inc., the company has provided strategic
information services for 30 years. Visit the Decision Resources Web site at
Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone),
+32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone),
+81.3.5401.2617 (fax), or email@example.com.
Decision Resources, Inc., is a world leader in primary and secondary
research publications, multi-client advisory services, and
customized consulting. More than 1,000 leading organizations and 100
percent of the 25 largest global pharmaceutical companies turn to
Decision Resources for their strategic planning, market development,
and competitive intelligence requirements. Founded as a subsidiary
of Arthur D. Little, Inc., Decision Resources has provided strategic
information services for 30 years. Decision Resources is
headquartered in Waltham, Massachusetts, with offices in Brussels,
London, and Tokyo. (PRNewsFoto)[AG]
WALTHAM, MA USA 03/03/2000